Why the study?
Does dexrazoxane prevent anthracycline-induced cardiotoxicity in patients receiving anthracycline chemotherapy?
Does dexrazoxane prevent anthracycline-induced cardiotoxicity in patients receiving anthracycline chemotherapy?
Dexrazoxane is an effective cardioprotective agent against anthracycline-induced cardiotoxicity, though its potential impact on oncologic response rates warrants careful consideration.
Answers are grounded in this paper and cite their sources.
May support dexrazoxane for anthracycline cardioprotection; leaves open questions on tumor response rates.
Dexrazoxane is a derivative of the powerful metal-chelating agent ethyl enediamine tetra acetic acid. Its cardioprotective effect is thought to be due to its ability to chelate iron and reduce the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. Preclinical studies have confirmed that dexrazoxane has significant activity as a cardioprotective agent against anthracycline-induced cardiotoxicity. Dexrazoxane is well-tolerated, with myelosuppression being the dose-limiting toxicity in Phase I trials. The cardioprotective utility of dexrazoxane has been further illustrated in a number of randomized trials. In addition no significant difference in survival has been observed between the dexrazoxane and control arms of these trials but, in one, a significantly lower response rate was observed in the dexrazoxane compared to placebo arm. Further trials are required to evaluate the efficacy of dexrazoxane in hematological malignancies as well as the adjuvant treatment of breast cancer. Its use in the paediatric setting and in the management of elderly patients with cardiac comorbidity also requires investigation. Recently, interest has focused on the use of dexrazoxane as an antidote for anthracycline extravasation. In addition the general cytoprotective activity of this drug requires further assessment, as well as selectivity in this context.
No takes yet. Share an insight, caveat, or question.
Robin L. Jones (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: